HONG KONG – Suzhou-based Alphamab Oncology Co. Ltd. pocketed $60 million in a series B financing to advance into the clinic with its potentially first-in-class PD-L1/CTLA4 bispecific antibody, KN-046, and to prepare for commercialization of its more advanced product, subcutaneous PD-L1 antibody KN-035 (envafolimab).